1. Academic Validation
  2. Rational Design of a Theranostic Agent Triggered by Endogenous Nitric Oxide in a Cellular Model of Alzheimer's Disease

Rational Design of a Theranostic Agent Triggered by Endogenous Nitric Oxide in a Cellular Model of Alzheimer's Disease

  • J Med Chem. 2022 Jul 14;65(13):9193-9205. doi: 10.1021/acs.jmedchem.2c00399.
Kang Lu 1 Yu Wang 2 Hao Zhang 2 Cuiqing Tian 1 Wenxiang Wang 1 Tian Yang 1 Baiwen Qi 2 Song Wu 1
Affiliations

Affiliations

  • 1 Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals, School of Pharmaceutical Sciences, Wuhan University, Wuhan, Hubei 430072, P. R. China.
  • 2 Department of Orthopaedic Trauma, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P. R. China.
Abstract

Oxidative damage caused by upregulated nitric oxide (NO) plays an important role in the pathogenesis of Alzheimer's disease (AD). Currently, stimulus-triggered theranostic agents have received much attention due to benefits on disease imaging and targeted therapeutic effects. However, the development of a theranostic agent triggered by NO for AD remains unexplored. Herein, through the mechanism analysis of the reaction between a fluorophore of 9,14-diphenyl-9,14-dihydrodibenzo[a,c]phenazine (DPAC) and NO, which we occasionally found and thereafter structure optimization of DPAC, a theranostic agent DPAC-(peg)4-memantine was fabricated. In an AD cellular model, DPAC-(peg)4-memantine exhibits NO sensing ability for AD imaging. Meanwhile, DPAC-(peg)4-memantine shows improved therapeutic by targeted drug release triggered by NO and sustained therapeutic effects owing to the synergetic antioxidative abilities via the anti-AD drug and NO scavenging. This work provides an unprecedented avenue for the studies on not only AD but also Other Diseases with NO upregulation.

Figures
Products